A Phase 2 interventional study of acalabrutinib and Placebo in Rheumatoid Arthritis, sponsored by Acerta Pharma BV. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-02.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Arthritis, Rheumatoid by AstraZeneca — 4 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · AstraZeneca.
Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, this one is the 31st largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 in phase 2, and was the 40th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 49 studies in Arthritis, Rheumatoid by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Germany and 3 more countries
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Brazil and 14 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–65
AstraZeneca · Sites in United States, Canada, China and 7 more countries
Ages 18–70
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 17 · Phase 3 6
First in 2003; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 72 across the 45 interventional studies, 1,575 across the 4 observational. Of the 44 that completed or were terminated, 21 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
2 of the studies in Arthritis, Rheumatoid by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.
A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The on-treatment period is 4 weeks with weekly visits to the clinic, followed by a 4-week safety follow-up period after the last dose of ACP-196/placebo. The study was to evaluate the safety, PK, PD, and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
Drug: acalabrutinib
Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
Drug: Placebo
Also known as: methotrexate
Also known as: methotrexate
Disease Activity Score 28-CRP (DAS28-CRP) at Week 4
Disease activity score 28 - C-reactive protein (DAS28-CRP) is a score to measure disease activity in patients with rheumatoid arthritis by aggregating data of 28 joints, and is calculated by the scores on scale using the following variables: The number of swollen and tender joints, CRP level, and patient's global assessment of disease activity. The total score of the DAS28 values may range from 2.0 to 10.0 while higher values mean a higher disease activity.
Time frame: 4 weeks
| Milestone | ACP-196 + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Started | 16 | 15 |
| Completed | 15 | 15 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Disease activity score 28 - C-reactive protein (DAS28-CRP) is a score to measure disease activity in patients with rheumatoid arthritis by aggregating data of 28 joints, and is calculated by the scores on scale using the following variables: The number of swollen and tender joints, CRP level, and patient's global assessment of disease activity. The total score of the DAS28 values may range from 2.0 to 10.0 while higher values mean a higher disease activity.
| Scores on scale | ACP 196 + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| Disease Activity Score 28-CRP (DAS28-CRP) at Week 4 | 5.40 ± 1.563 | 5.05 ± 1.639 |
Collected over From the date of the first dose of study drug up to 30 days after the date of the last dose of study drug, up to 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ACP-196 + Methotrexate | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Placebo + Methotrexate | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Event | ACP-196 + Methotrexate | Placebo + Methotrexate |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/16 | 0/15 |
| DiarrheaGastrointestinal disorders | 1/16 | 1/15 |
| NauseaGastrointestinal disorders | 1/16 | 1/15 |
| Oedema peripheralGeneral disorders | 1/16 | 1/15 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/16 | 1/15 |
| FallInjury, poisoning and procedural complications | 0/16 | 1/15 |
| Hip FractureInjury, poisoning and procedural complications | 0/16 | 1/15 |
| Blood uric acid increasedInvestigations | 0/16 | 1/15 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/16 | 1/15 |
| LethargyNervous system disorders | 0/16 | 1/15 |
Intent-to-treat population, which included all randomized subjects
| Age, Categorical(Participants) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 12 | 22 |
| >=65 years | 6 | 3 | 9 |
| Age, Continuous(years) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| Mean | 61.3 ± 7.21 | 56.8 ± 7.92 | 59.1 ± 7.78 |
| Sex: Female, Male(Participants) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| Female | 14 | 13 | 27 |
| Male | 2 | 2 | 4 |
| Race (NIH/OMB)(Participants) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 5 |
| White | 14 | 10 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| United States | 16 | 15 | 31 |
| DAS28-CRP at baseline(Scores on Scale) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| Mean | 6.29 ± 1.242 | 6.29 ± 1.220 | 6.29 ± 1.211 |
| Duration of rheumatoid arthritis since initial diagnosis(years) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| Mean | 10.3 ± 7.52 | 7.8 ± 8.12 | 9.1 ± 7.78 |
| Methotrexate dosing at baseline(mg/week) | ACP-196 + Methotrexate | Placebo + Methotrexate | Total |
|---|---|---|---|
| Mean | 16.9 ± 6.49 | 17.7 ± 5.22 | 17.3 ± 5.82 |
The record gives a start of Apr 2015, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib